Product Description
AT03-65 is a recombinant anti-CLDN6 monoclonal antibody conjugated to AxcynDOT™, a proprietary payload developed by Axcynsis with a differentiated mechanism of action and broad anti-cancer activities. AT03-65 is designed to target advanced, recurrent, or metastatic CLDN6+ solid tumors in patients who have progressed on or after standard systemic treatment or for whom no standard therapies are available. (Sourced from: https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c)
Mechanisms of Action: CLDN6 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Axcynsis Therapeutics Pte Ltd
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06809114 |
AT0365-P1-01 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-12-01 |
50% |
2026-01-31 |
Recent News Events
Date |
Type |
Title |
|---|